Renalis Company Overview
Renalis develops FDA-cleared prescription digital therapeutics for the treatment of pelvic health disorders, filling a void in the market for accessible solutions for first-line therapy for the 33 million+ people struggling with these disorders and removing barriers to equity and access to treatment. Renalis was named to the 2022 CB Insights Digital Health 150, celebrating private companies transforming healthcare with digital technology. Renalis has raised $1.67 million with investments from the Healthcare Collaboration Fund and JumpStart, Inc.
Renalis Stock Price
The stock price of Renalis can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
Buy Renalis Stock
If you would like to buy shares in Renalis, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Renalis stock availability. Note: inquiries are non-binding and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Renalis as well.
Renalis Management
| Name | Position |
|---|---|
| Missy Lavender | CEO |
